FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2412187584> ?p ?o ?g. }

• W2412187584 endingPage "66" @default.
• W2412187584 startingPage "57" @default.
• W2412187584 abstract "Glioblastomas (GBMs) are aggressive brain tumours with a dismal prognosis, despite combined surgery, radio- and chemotherapy. Close to 90 % of all GBMs harbour a deregulated PI3K pathway, which is essential in regulating central cellular functions such as proliferation, cell growth, motility and survival. Thus, PI3K represents a potential target for molecular therapy in GBM. We investigated the anti-tumour efficacy of the PI3K inhibitor buparlisib (NVP-BKM120) in GBM cell lines in vitro and in vivo, when treatment was initiated after MRI-confirmed tumour engraftment. We found that buparlisib inhibited glioma cell proliferation in a dose dependent manner, demonstrated by MTS assay, manual cell count and BrdU incorporation. A dose dependent increase in apoptosis was observed through flow cytometric analysis. Furthermore, by immunocytochemistry and western blot, we found a dose dependent inhibition of Akt phosphorylation. Moreover, buparlisib prolonged survival of nude rats harboring human GBM xenografts in three independent studies and reduced the tumours' volumetric increase, as determined by MRI. In addition, histological analyses of xenograft rat brains showed necrotic areas and change in tumour cell nuclei in buparlisib-treated animals. The rats receiving buparlisib maintained their weight, activity level and food- and water intake. In conclusion, buparlisib effectively inhibits glioma cell proliferation in vitro and growth of human GBM xenografts in nude rats. Moreover, the compound is well tolerated when administered at doses providing anti-tumour efficacy. Thus, buparlisib may have a future role in glioma therapy, and further studies are warranted to validate this compound for human use." @default.
• W2412187584 created "2016-06-24" @default.
• W2412187584 creator A5012686013 @default.
• W2412187584 creator A5020808093 @default.
• W2412187584 creator A5033604001 @default.
• W2412187584 creator A5064081540 @default.
• W2412187584 creator A5064110734 @default.
• W2412187584 creator A5078008340 @default.
• W2412187584 creator A5079760047 @default.
• W2412187584 creator A5087051881 @default.
• W2412187584 creator A5089971932 @default.
• W2412187584 date "2016-06-09" @default.
• W2412187584 modified "2023-10-13" @default.
• W2412187584 title "Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats" @default.
• W2412187584 cites W1893588436 @default.
• W2412187584 cites W1980889025 @default.
• W2412187584 cites W2014620054 @default.
• W2412187584 cites W2018390208 @default.
• W2412187584 cites W2020217107 @default.
• W2412187584 cites W2054917860 @default.
• W2412187584 cites W2088460013 @default.
• W2412187584 cites W2090185653 @default.
• W2412187584 cites W2102348612 @default.
• W2412187584 cites W2102839088 @default.
• W2412187584 cites W2109816625 @default.
• W2412187584 cites W2116852577 @default.
• W2412187584 cites W2120191503 @default.
• W2412187584 cites W2125096000 @default.
• W2412187584 cites W2151010413 @default.
• W2412187584 cites W2155295856 @default.
• W2412187584 cites W2156928849 @default.
• W2412187584 cites W2158681922 @default.
• W2412187584 cites W2160382843 @default.
• W2412187584 cites W2165404212 @default.
• W2412187584 cites W2165871546 @default.
• W2412187584 cites W2168485476 @default.
• W2412187584 cites W4238567307 @default.
• W2412187584 cites W4243287697 @default.
• W2412187584 doi "https://doi.org/10.1007/s11060-016-2158-1" @default.
• W2412187584 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4972854" @default.
• W2412187584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27283525" @default.
• W2412187584 hasPublicationYear "2016" @default.
• W2412187584 type Work @default.
• W2412187584 sameAs 2412187584 @default.
• W2412187584 citedByCount "22" @default.
• W2412187584 countsByYear W24121875842017 @default.
• W2412187584 countsByYear W24121875842018 @default.
• W2412187584 countsByYear W24121875842019 @default.
• W2412187584 countsByYear W24121875842020 @default.
• W2412187584 countsByYear W24121875842021 @default.
• W2412187584 countsByYear W24121875842022 @default.
• W2412187584 crossrefType "journal-article" @default.
• W2412187584 hasAuthorship W2412187584A5012686013 @default.
• W2412187584 hasAuthorship W2412187584A5020808093 @default.
• W2412187584 hasAuthorship W2412187584A5033604001 @default.
• W2412187584 hasAuthorship W2412187584A5064081540 @default.
• W2412187584 hasAuthorship W2412187584A5064110734 @default.
• W2412187584 hasAuthorship W2412187584A5078008340 @default.
• W2412187584 hasAuthorship W2412187584A5079760047 @default.
• W2412187584 hasAuthorship W2412187584A5087051881 @default.
• W2412187584 hasAuthorship W2412187584A5089971932 @default.
• W2412187584 hasBestOaLocation W24121875841 @default.
• W2412187584 hasConcept C126322002 @default.
• W2412187584 hasConcept C142724271 @default.
• W2412187584 hasConcept C1491633281 @default.
• W2412187584 hasConcept C150903083 @default.
• W2412187584 hasConcept C190283241 @default.
• W2412187584 hasConcept C203014093 @default.
• W2412187584 hasConcept C207001950 @default.
• W2412187584 hasConcept C2776694085 @default.
• W2412187584 hasConcept C2778227246 @default.
• W2412187584 hasConcept C502942594 @default.
• W2412187584 hasConcept C54355233 @default.
• W2412187584 hasConcept C553184892 @default.
• W2412187584 hasConcept C55493867 @default.
• W2412187584 hasConcept C62112901 @default.
• W2412187584 hasConcept C71924100 @default.
• W2412187584 hasConcept C75217442 @default.
• W2412187584 hasConcept C86554907 @default.
• W2412187584 hasConcept C86803240 @default.
• W2412187584 hasConcept C98274493 @default.
• W2412187584 hasConceptScore W2412187584C126322002 @default.
• W2412187584 hasConceptScore W2412187584C142724271 @default.
• W2412187584 hasConceptScore W2412187584C1491633281 @default.
• W2412187584 hasConceptScore W2412187584C150903083 @default.
• W2412187584 hasConceptScore W2412187584C190283241 @default.
• W2412187584 hasConceptScore W2412187584C203014093 @default.
• W2412187584 hasConceptScore W2412187584C207001950 @default.
• W2412187584 hasConceptScore W2412187584C2776694085 @default.
• W2412187584 hasConceptScore W2412187584C2778227246 @default.
• W2412187584 hasConceptScore W2412187584C502942594 @default.
• W2412187584 hasConceptScore W2412187584C54355233 @default.
• W2412187584 hasConceptScore W2412187584C553184892 @default.
• W2412187584 hasConceptScore W2412187584C55493867 @default.
• W2412187584 hasConceptScore W2412187584C62112901 @default.
• W2412187584 hasConceptScore W2412187584C71924100 @default.
• W2412187584 hasConceptScore W2412187584C75217442 @default.
• W2412187584 hasConceptScore W2412187584C86554907 @default.

• next